Warning Letter Close-Outs – September 2022
The US FDA released one close-out letter in September, resolving a warning issued to a California device firm in 2017.
You may also be interested in...
Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a strong position in an emerging field.
Scrip’s Joseph Haas and Jessica Merrill discuss the US FTC’s oversight of the Amgen/Horizon deal and what it might portend for biopharma M&A with Leerink Partners' Dan Lepanto and ZS partner Cody Powers.
The approval for Invitae’s cancer risk diagnostic test opens the door for more tests of its kind.